

Asst. Prof. Birol Tibet, BA, MA, MSc, MD, PhD

Founding Director, BAU HTA

Assistant Professor of Public Health, Bahçeşehir University Faculty of Medicine (BAU MED)

Portfolio: Health Economics, HEOR, Value Assessment and Market Access; Health Policy, Coverage, Reimbursement, Procurement and Health Systems

Asst. Prof. Birol Tibet is a physician, public health academic, health economist, healthcare manager, and strategic advisor working at the intersection of **health technology assessment (HTA), health economics and outcomes research (HEOR), value assessment, market access, pricing, reimbursement, procurement, health policy, and health systems strengthening**. He serves as the **Founding Director of BAU HTA — Bahçeşehir University Health Technology Assessment Platform**, where his leadership portfolio focuses on Health Economics, HEOR, Value Assessment and Market Access, as well as Health Policy, Coverage, Reimbursement, Procurement, and Health Systems.

At Bahçeşehir University, Dr. Tibet serves as **Assistant Professor of Public Health** at the Faculty of Medicine and **Head of the Department of Family Medicine**. He teaches research methodology and public health in the English-language programmes of the Faculties of Medicine and Pharmacy, contributing to the development of future physicians, pharmacists, and health professionals with stronger capacity in evidence-informed and value-oriented decision-making.

Dr. Tibet's academic background combines medicine, management, economics, and public health. He holds an **MD** from Dokuz Eylül University, a **BA in Business Administration** from Anadolu University, an **MSc in Health Economics, Policy and Law** with specialization in Health Economics from Erasmus University Rotterdam, an **MA in Hospital and Healthcare Management** from Istanbul University, and a **PhD in Public Health** from Istanbul University. His doctoral research focused on improving access to orphan drugs in rare diseases, reflecting his long-standing interest in equitable access, value assessment, and policy design for complex and high-impact health technologies.

Before joining Bahçeşehir University, Dr. Tibet held a wide range of public-sector, academic, research, and advisory roles. Between 2010 and 2022, he served in multiple positions within the **Ministry of Health of Türkiye**, working across health economics, financing policies, regulation, market access, clinical quality, health system reform, public hospitals, county health administration, family medicine, non-communicable diseases, and migrant health services. These roles gave him first-hand experience in how

evidence, regulation, reimbursement, procurement, service delivery, institutional capacity, and political feasibility interact in real-world health decision-making.

His public-sector experience includes serving as **Contact Person for Health Economics, Regulation and Market Access** at the Health Institutes of Türkiye, **Health Economics and Financing Policies Expert** at the Turkish Institute for Health Policies, **Presidential Advisor** within the Public Hospitals Agency of Türkiye, and member of strategy and implementation teams involved in national health system transformation and clinical quality improvement. This background enables him to approach HTA and market access not only as technical disciplines, but also as practical instruments for policy, coverage, reimbursement, procurement, innovation, and health-system performance.

Dr. Tibet has also contributed to research and innovation ecosystems. He served as **Chair of the Management Committee, Assistant Director, and Quality Management Manager** at the Izmir Biomedicine and Genome Center. He also worked as a **World Health Organization consultant** on health policies and simulation modelling related to risk factors for non-communicable diseases. These roles strengthened his practical understanding of biomedical research infrastructure, health innovation, evidence generation, and the translation of scientific work into policy-relevant outputs.

Since 2017, Dr. Tibet has provided independent consultancy in **market access, HTA, HEOR, health policy, health economics, and health management**, with a focus on pharmaceuticals, medical devices, biotechnology products, and innovative health technologies. His international consulting experience includes work on strengthening pricing and reimbursement systems for pharmaceuticals and medical devices in Ukraine under the **Management Sciences for Health SAFEMed Project**.

Internationally, Dr. Tibet is actively engaged in scientific and policy platforms related to HTA, public health, innovation, and global health preparedness. Within **Health Technology Assessment International (HTAi)**, he has served as Vice-Chair of the Early Career Network, Steering Committee Member of the Public Health Interest Group, Executive Member of the Regional Engagement Committee for the 2026 Annual Meeting, and Member of the International Scientific Programme Committee for the 2027 Annual Meeting. He has contributed to regional HTA meetings and policy dialogues, including activities focused on Central Asia and emerging HTA systems.

His broader international engagements include serving as a **Member of the Türkiye Working Group** at the Pandemic Readiness, Implementation, Monitoring, and Evaluation Commission led by the National University of Singapore and *The Lancet*, a **NextGen Scholar** at *The Lancet Regional Health – Europe* Commission on Climate Change, Migration, Displacement and Health, and the **Turkish National Mirror Group Representative** in the European Rare Diseases Research Alliance under Horizon Europe.

Dr. Tibet's scholarly work reflects his ability to connect scientific methods, policy relevance, and applied decision-making. His publications and scientific outputs include work in journals such as *The Lancet Regional Health – Europe*, *Frontiers in Endocrinology*, *Value in Health*, and the *International Journal of Technology Assessment in Health Care*, as well as book chapters and reports on pharmaceutical market access, health technology innovation ecosystems, cost-containment policies, rare diseases, health inequalities, clinical quality, economic evaluation, and health-system performance.

As Founding Director of BAU HTA, Dr. Tibet leads the development of an interdisciplinary academic platform designed to integrate **education, research, advisory work, capacity building, policy engagement, and regional collaboration** in HTA, HEOR, market access, and value-based healthcare. BAU HTA brings together expertise across health economics, clinical sciences, outcomes research, surgical and procedural technologies, evidence synthesis, real-world evidence, strategic projects, technology transfer, and research associate development.

Through BAU HTA, Dr. Tibet aims to support universities, public institutions, industry, researchers, healthcare organizations, NGOs, and international partners in generating better evidence, assessing value more rigorously, and making more informed decisions about health technologies. The platform's regional orientation focuses on Türkiye and neighboring regions, including Eastern Europe, Central Asia, the Middle East, and North Africa, with an emphasis on academic rigor, applied relevance, and regional capacity development.

Dr. Tibet's profile is distinguished by his ability to bridge **local health-system realities and international standards, academic methods and market access strategy, and public-sector policy needs and private-sector innovation challenges**. His work is particularly relevant for organizations seeking strategic support in HTA, HEOR, pricing and reimbursement, evidence generation, early HTA, real-world evidence, rare diseases, innovative therapies, medical devices, biotechnology products, and health innovation pathways.

With more than a decade of leadership across public institutions, academia, research organizations, international networks, and consulting engagements, Dr. Tibet brings a combination of technical expertise, institutional insight, strategic perspective, and regional connectivity. Through BAU HTA, he is building a platform dedicated to better evidence, stronger value demonstration, improved access strategies, and more sustainable health-system decisions across Türkiye and the broader region.